Related Experiment Video
Updated: Aug 8, 2026
Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
Protective effects of compound FLZ on beta-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and
1Department of Pharmacology, Institute of Materia Medica, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100050, China.
Aim:
To study the protective effects of compound FLZ, a novel synthetic analogue of natural squamosamide, on learning and memory impairment and lesions of the hippocampus caused by icv injection of beta-amyloid(25-35)(Abeta(25-35)) in mice.
Methods:
Mice were icv injected with the Abeta(25-35) (15 nmol/mouse), and then treated with oral administration of 75 mg/kg or 150 mg/kg of FLZ once daily for 16 consecutive days. The impairment of learning and memory in mice were tested using step-down test and Morris water maze test. The content of malondialdehyde (MDA) and the expressions of acetylcholinesterase (AChE), Bax, and Bcl-2 in the CA1 region of the mouse hippocampus were measured by biochemical and immunohistochemical analysis, respectively. The pathological damages of hippocampus were observed using a microscope.
Results:
FLZ (75 mg/kg, 150 mg/kg) significantly attenuated Abeta(25-35)-induced impairment of learning and memory in the step-down test and Morris water maze test. FLZ also reduced pathological damages to the hippocampus induced by Abeta(25-35). Furthermore, FLZ prevented the increase of AChE and Bax, and the decrease of Bcl-2 immunoreactive cells in the CA1 region of the hippocampus, and reduced the increase of MDA content in the hippocampus in mice injected with Abeta(25-35).
Conclusion:
FLZ has protective action against the impairment of learning and memory and pathological damage to the hippocampus induced by icv injection of Abeta(25-35) in mice.
Insights
Compound FLZ protects against beta-amyloid-induced memory loss and hippocampal damage in mice. This novel squamosamide analogue shows promise for treating Alzheimer
Area of Science:
- Neuroscience
- Pharmacology
- Biochemistry
Background:
- Alzheimer's disease is characterized by beta-amyloid (Abeta) peptide accumulation, leading to cognitive decline and hippocampal damage.
- Natural product analogues are being explored for neuroprotective properties against Abeta toxicity.
- Compound FLZ, a synthetic analogue of squamosamide, is investigated for its potential therapeutic effects.
Purpose of the Study:
- To evaluate the protective effects of compound FLZ against Abeta(25-35)-induced learning and memory impairment.
- To assess the impact of FLZ on hippocampal lesions and oxidative stress markers.
- To determine FLZ's influence on key proteins involved in apoptosis and neurotransmission within the hippocampus.
Main Methods:
- Mice received intracerebroventricular (ICV) injections of Abeta(25-35) to induce cognitive deficits and hippocampal damage.
- Mice were treated orally with FLZ (75 mg/kg or 150 mg/kg) daily for 16 days.
- Learning and memory were assessed using the step-down and Morris water maze tests. Hippocampal tissue was analyzed for malondialdehyde (MDA), acetylcholinesterase (AChE), Bax, and Bcl-2 levels, alongside pathological examination.
Main Results:
- FLZ treatment significantly ameliorated Abeta(25-35)-induced deficits in learning and memory.
- FLZ reduced pathological damage in the hippocampus and decreased malondialdehyde (MDA) content.
- FLZ prevented the upregulation of acetylcholinesterase (AChE) and Bax, and the downregulation of Bcl-2 in the hippocampal CA1 region.
Conclusions:
- Compound FLZ demonstrates significant neuroprotective action against Abeta(25-35)-induced cognitive impairment and hippocampal pathology.
- FLZ mitigates oxidative stress and modulates apoptotic pathways in the hippocampus.
- FLZ holds potential as a therapeutic agent for conditions involving Abeta-induced neurodegeneration.
